Targeted Therapy: Attacking Cancer with Molecular and Immunological Targeted Agents

Wilkes, Gail M.

doi:10.4103/apjon.apjon_79_17

Cited by 63 publications

(32 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Poly ADP ribose polymerase (PARP) inhibitors are currently the most promising agents in this group, based on the similarity of this subtype to ovarian cancers. [73][74][75][76][77] Alternative holistic approaches are being continuously sought as the World Health Organization (WHO) forecasts that approximately 80% of the global population would use one or the other form of alternative medicine in their life time. 78 In this report, we have described the application of green nanotechnology to holistic Ayurvedic medicine.…”

Section: Discussion Related To Pilot Clinical Trial Investigationsmentioning

confidence: 99%

<p>New Approaches in Breast Cancer Therapy Through Green Nanotechnology and Nano-Ayurvedic Medicine – Pre-Clinical and Pilot Human Clinical Investigations</p>

Khoobchandani

Katti

Karikachery

et al. 2020

IJN

110

View full text Add to dashboard Cite

The overarching objective of this investigation was to investigate the intervention of green nanotechnology to transform the ancient holistic Ayurvedic medicine scientifically credible through reproducible formulations and rigorous pre-clinical/clinical evaluations. Methods: We provide, herein, full details: (i) on the discovery and full characterization of gold nanoparticles-based Nano Swarna Bhasma (henceforth referred to as NSB drug); (ii) In vitro anti-tumor properties of NSB drug in breast tumor cells; (iii) pre-clinical therapeutic efficacy studies of NSB drug in breast tumor bearing SCID mice through oral delivery protocols and (iv) first results of clinical translation, from mice to human breast cancer patients, through pilot human clinical trials, conducted according to the Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy (abbreviated as AYUSH) regulatory guidelines of the Government of India in metastatic breast cancer patients. Results: The preclinical in vitro and in vivo investigations, in breast tumor bearing mice, established unequivocally that the NSB Nano-Ayurvedic medicine-gold nanoparticles-based drug is highly effective in controlling the growth of breast tumors in a dose dependent fashion in vivo. These encouraging pre-clinical results prompted us to seek permission from the Indian Government's holistic medicine approval authority, AYUSH, for conducting clinical trials in human patients. Patients treated with the NSB drug capsules along with the "standard of care treatment" (Arm B) exhibited 100% clinical benefits when compared to patients in the treatment Arm A, thus indicating the tremendous clinical benefits of NSB drug in adjuvant therapy. Conclusion: We have succeeded in clinically translating, from mice to humans, in using proprietary combinations of gold nanoparticles and phytochemicals to develop the Nano-Ayurvedic drug: Nano Swarna Bhasma (NSB), through innovative green nanotechnology, for treating human metastatic breast cancer patients.

show abstract

Section: Discussion Related To Pilot Clinical Trial Investigationsmentioning

confidence: 99%

<p>New Approaches in Breast Cancer Therapy Through Green Nanotechnology and Nano-Ayurvedic Medicine – Pre-Clinical and Pilot Human Clinical Investigations</p>

Khoobchandani

Katti

Karikachery

et al. 2020

IJN

110

View full text Add to dashboard Cite

show abstract

“…With the development of gene technology, we can classify different cancers based on their speci c molecular signals. These advances have further allowed the identi cation of molecular therapeutic targets speci c to cancer cells, thus providing a framework whereby therapies can be speci cally matched to corresponding molecular targets (4). By targeting the complex network of signaling pathways that regulates cell proliferation, angiogenesis, and apoptosis (cell death), researchers have developed new targeted agents that interfere with the growth and proliferation of cancer cells (5).…”

Section: Introductionmentioning

confidence: 99%

Adverse Reactions of Targeted Therapy in Cancer Patients: A Retrospective Study of Hospital Medical Data in China

Du¹,

Larcher

Tang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The adverse reactions (ADR) of targeted therapy were closely related to the treatment efficacy, quality of life (QoL) and prognosis of cancer patients. However, few studies analyzed the ADR of targeted therapy and their effects on cancer patients. This study was conducted to describe the incidence and characteristics of ADR in cancer patients with targeted therapy and outcomes associated with ADR based on hospital medical data.Methods: A retrospective secondary data analysis was conducted using ADR data in hospital medical record collected from a cohort (n=2,703 with targeted therapy) in three hospitals of Henan, China from January 2018 to December 2019. The type, classification, occurrence time and duration of ADR, medication compliance and drug application, QoL, disease progress and survival of patients were analyzed.Results: A total of 485 patients met the inclusion criteria. 296 (61.0%) patients had ADR during target therapy. The top five ADR in this study were damage to skin, fatigue, mucosal damage, hypertension and gastrointestinal discomfort. 62.1% of the ADR were mild to moderate, more than half of the ADR occurred within one month, 68.6% ADR lasted more than one month. Older patients (P=0.022) and patients with lower education level (P=0.036), more than 2 comorbidities (P=0.021), longer medication time (P=0.022), drug combination (P=0.033) and intravenous administration (P=0.019) were more likely to have ADR. Those who had ADR were more likely to stop taking (P=0.025), change (P=0.010), adjust (P=0.019), or not take the medicine on time (P=0.022), or undergo cancer recurrence (P=0.027) and show higher rates of metastasis (P=0.009) .Conclusion: The incidence of ADR in cancer patients during targeted therapy was high. Age, education level, comorbidity and medication strategy can affect ADR. Furthermore, ADR would affect the treatment and prognosis of patients. We should pay more attention to these ADRs and develop effective management strategies.

show abstract

“…Approximately 70 % of cancer related deaths occur in developing countries. The International Agency for Research on Cancer (IARC) estimated that the annual number of new cancer cases would rise to an estimated 21.7 million in 2030 along with 13.0 million deaths (Wilkes, 2018[ 39 ]; Dalton et al, 2019[ 6 ]). Among the various strategies for cancer treatment, chemotherapy is often known as the most widely used method to prevent and treat cancer.…”

Section: Introductionmentioning

confidence: 99%

In vitro anticancer activity of Scrophularia amplexicaulis extracts on MCF-7 and WEHI-164 cell line

Valiyari

Beiranvand

Samimi

et al. 2020

EXCLI Journal; 19:Doc1341; ISSN 1611-2156

View full text Add to dashboard Cite

Targeted Therapy: Attacking Cancer with Molecular and Immunological Targeted Agents

Cited by 63 publications

References 25 publications

<p>New Approaches in Breast Cancer Therapy Through Green Nanotechnology and Nano-Ayurvedic Medicine – Pre-Clinical and Pilot Human Clinical Investigations</p>

<p>New Approaches in Breast Cancer Therapy Through Green Nanotechnology and Nano-Ayurvedic Medicine – Pre-Clinical and Pilot Human Clinical Investigations</p>

Adverse Reactions of Targeted Therapy in Cancer Patients: A Retrospective Study of Hospital Medical Data in China

In vitro anticancer activity of Scrophularia amplexicaulis extracts on MCF-7 and WEHI-164 cell line

Contact Info

Product

Resources

About